JCL Roundtable: Lipid-lowering drugs in those older than 75 years of age

Journal of Clinical Lipidology

Volumn 8, Issue 6, 2014, Pages 533-541

  Brown, W Virgil ^a   Bittner, Vera A ^b   McKenney, James M ^c   Ziajka, Paul E ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c National Clinical Research Inc   (United States)

^d Florida Lipid Institute   (United States)

Author keywords

Atherosclerosis; Blood cholesterol; Elderly population; Lipid drugs; Vascular disease

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

AGED; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VASCULAR DISEASE; BLOOD; CARDIOVASCULAR DISEASES; EXPERT WITNESS; HYPERLIPIDEMIAS; MEDICAL SOCIETY; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; CHOLESTEROL; EXPERT TESTIMONY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84928825575     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.09.009     Document Type: Review

References (17)

1. M.J. Pletcher, C.T. Sibley, M. Pignone, E. Vittinghoff, and P. Greenland Interpretation of the coronary artery calcium score in combination with conventional cardiovascular risk factors. The Multi-Ethnic Study of Atheroscoserosis (MESA) Circulation 128 2013 1076 1084
2. A.S. Go, D. Mozaffarian, V.L. Roger, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Executive summary: Heart disease and stroke statistics - 2014 update. A report from the American Heart Association Circulation 129 3 2014 399 410
3. Cholesterol Treatment Trialists' Collaboration The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individuals from 27 randomized trials Lancet 380 2012 581 590
4. Heart Protection Study Collaborative Group MRC.BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial Lancet 360 2002 7 22
5. R.J. Glynn, W. Koenig, B.C. Nordestgaard, J. Shepherd, and P.M. Ridker Rosuvastatin for primary prevention in older persons with elevated c-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomzied trial Ann Intern Med 152 2010 488 496
6. N.K. Wenger, S.J. Lewis, D.M. Herrington, V. Bittner, and F.K. Welty Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease Ann Intern Med 147 2007 1 9
7. G. SAvarese, A.M. Gotto, S. Paolillo, and et al. Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease A Meta-Analysis J Am Coll Cardiol 62 22 2013 2090 2099
8. N. Sattar, D. Preiss, H.M. Murray, and et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials Lancet 375 2010 735 742
9. D.D. Waters, J.E. Ho, D.A. DeMicco, and et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials J Am Coll Cardiol 57 14 2011 1535 1545
10. D. Preiss, S.R. Seshasai, P. Welsh, and et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy; a meta-analysis JAMA 305 2011 2556 2564
11. L.D. Lazar, M.J. Pletcher, P.G. Coxson, K. Bibbins-Domingo, and L. Goldman Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era Circulation 124 2011 146 153
12. T. Feldman, M. Davidson, A. Shah, and et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe co-administered with simvastatin in older versus younger patients with primary hypercholesterolemia: A post Hoc analysis of subpopulations from three pooled clinical trials Clin Ther 28 2006 849 859
13. M. Sano, K.L. Bell, D. Galasko, and et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 77 2011 556 563
14. S. Grundy, J.I. Cleeman, B.M. Rifkind, and L.H. Kuller Cholesterol lowering in the elderly population Arch Int Med 159 1999 1670 1678
15. D. Hunt, P. Young, J. Simes, and et al. Benefits of pravastatin on CVD events and mortality in older patients with cad are equal or exceed those seen in younger patients: Results from the LIPID trial Ann Int Med 134 2001 931 940
16. R.N. Lemaitre, B.M. Psaty, S.R. Heckbert, R.A. Kronmal, A.B. Newman, and G.L. Burke Therapy with HMG-Co reductase inhibitors and associated risk of incident CVD events in older adults Arch Int Med 162 2002 1395 1400
17. J. Shepherd, G.J. Blauw, M.B. Murphy, and et al. Pravastatin in Elderly Individuals at Risk of Vascular Disease (PROSPER): A Randomized Controlled Trial Lancet 360 2002 1623 1630